Article
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 1990
Kirkwood J M, Ernstoff M S, Trautman T, Hebert G, Nishida Y, Davis C A, Balzer J, Reich S, Schindler J, Rudnick S A
Abstract excerpt
Interferon-gamma (IFN gamma), as produced by recombinant DNA technology, has shown a wide range of immunomodulatory activity in vitro and in vivo. Clinical studies have attempted to establish a dose-response relationship to define optimal dosage ranges for induction of effector cell function and host response in patients with cancer. We conducted a randomized trial to test the in vivo biologic activity of five...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
